CD40 and cancer: Hassan et al. used antigen-bearing MWCNTs to deliver immunoadjuvants such as cytosine-phosphate-guanine oligodeoxynucleotide (CpG), anti-CD40 Ig (CD40), and ovalbumin (OVA) antigen to trigger an immune response against OVA-expressing cancer cells.